Oy Leiras Finland Ab is now part of the European Nycomed Group. The roots of Leiras in Finland date back to 1911, and since 1946 the company has been called Leiras. Over the decades, we have worked in close cooperation with Finnish healthcare professionals and have established a well-known position as a reliable and competent partner for the medical and pharmaceutical community in our country. Our position on the Finnish market is based not only on the long history and strong Leiras brand, but also on our skills in successfully introducing several products from different licensors. We are committed to cooperating closely with our licensors in order to make every product a success in Finland. Here our in-depth market knowledge and experience of working with a variety of licensors is a key factor in our success. Our strong areas with dedicated sales force and marketing networks cover GPs, hospital specialists and pharmacies in the following therapy groups: * cardiovascular diseases * osteoporosis * arthrosis * special products for hospital usage (i.e. cardiology, soft tissue surgery, endocrinology and gastroenterology) In Self Care, we are clearly the second biggest marketer in Finland, with products for cough & cold, osteoporosis and vitamins as our strongest areas. We are one of the biggest subsidiaries of Nycomed. In 2004 we were ranked number eight in terms of revenue and number three in terms of volume in the Finnish pharmaceutical market Our revenue was

Rx portfolio: * Diabetes (type 2 ): DPP-IV inhibitors + other new approaches. * Cardiovascular disease: hypertension; cholesterol lowering drugs and antihypertensives * Gastroenterological disease: proton pump inhibitors; TNF-like products * CNS disease: new modern epilepsy drugs, new Alzheimer's disease drugs, anti-psychotics, anti-depressants, Parkinson's disease disease, modern migraine drugs (NOT triptans) * Hospital sector: - i.v. antibiotics - semi modern cancer drugs - antineoplastics (EPH 3 group L01X) - adjunctive products for cancer - immunostimulating agents, new antiemetics, immunosuppressive agents * OTC portfolio: - topical creams/ointments containing some active pharmaceutical ingredient (for skin infections, acne, psoriasis) - smoking cessation products - laxatives and other products for GI problems

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.